186 related articles for article (PubMed ID: 7308269)
1. Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide.
Keller E; Hoppe-Seyler G; Mumm R; Schollmeyer P
Eur J Clin Pharmacol; 1981; 20(1):27-33. PubMed ID: 7308269
[TBL] [Abstract][Full Text] [Related]
2. Furosemide kinetics and dynamics in patients with cirrhosis.
Villeneuve JP; Verbeeck RK; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1986 Jul; 40(1):14-20. PubMed ID: 3720175
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of furosemide in patients with hepatic cirrhosis.
González G; Arancibia A; Rivas MI; Caro P; Antezana C
Eur J Clin Pharmacol; 1982; 22(4):315-20. PubMed ID: 7106167
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamic effects of furosemide in patients with liver cirrhosis.
Traeger A; Häntze R; Penzlin M; Krombholz B; Reinhardt M; Keil E; Jorke D
Int J Clin Pharmacol Ther Toxicol; 1985 Mar; 23(3):129-33. PubMed ID: 3997298
[TBL] [Abstract][Full Text] [Related]
5. Furosemide kinetics in patients with hepatic cirrhosis with ascites.
Fuller R; Hoppel C; Ingalls ST
Clin Pharmacol Ther; 1981 Oct; 30(4):461-7. PubMed ID: 7285480
[TBL] [Abstract][Full Text] [Related]
6. Furosemide disposition in cirrhosis.
Verbeeck RK; Patwardhan RV; Villeneuve JP; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1982 Jun; 31(6):719-25. PubMed ID: 7075120
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of torasemide and furosemide in patients with diuretic resistant ascites.
Gentilini P; La Villa G; Marra F; Carloni V; Melani L; Foschi M; Cotrozzi G; Quartini M; Chibbaro G; Tommasi AC; Bernareggi A; Simoni A; Buzzelli G; Laffi G
J Hepatol; 1996 Oct; 25(4):481-90. PubMed ID: 8912147
[TBL] [Abstract][Full Text] [Related]
8. Renal tubular secretion and effects of furosemide.
Odlind B; Beermann B
Clin Pharmacol Ther; 1980 Jun; 27(6):784-90. PubMed ID: 7379446
[TBL] [Abstract][Full Text] [Related]
9. [Mechanism of action of xipamide and its classification as a "low ceiling diuretic". Pharmacodynamic-pharmacokinetic studies in healthy volunteers and in kidney and liver patients].
Knauf H; Mutschler E
Arzneimittelforschung; 2005; 55(1):1-14. PubMed ID: 15727159
[TBL] [Abstract][Full Text] [Related]
10. Elimination of furosemide in healthy subjects and in those with renal failure.
Beermann B; Dalén E; Lindström B
Clin Pharmacol Ther; 1977 Jul; 22(1):70-8. PubMed ID: 872498
[TBL] [Abstract][Full Text] [Related]
11. The influence of indomethacin on the pharmacokinetics, diuretic response and hemodynamics of furosemide in the dog.
Data JL; Rane A; Gerkens J; Wilkinson GR; Nies AS; Branch RA
J Pharmacol Exp Ther; 1978 Aug; 206(2):431-8. PubMed ID: 682123
[TBL] [Abstract][Full Text] [Related]
12. Disposition and diuretic effect of furosemide in the nephrotic syndrome.
Keller E; Hoppe-Seyler G; Schollmeyer P
Clin Pharmacol Ther; 1982 Oct; 32(4):442-9. PubMed ID: 7116760
[TBL] [Abstract][Full Text] [Related]
13. Lack of effect of cimetidine on furosemide kinetics and dynamics in patients with hepatic cirrhosis.
Sanchis Closa A; Lambert C; du Souich P
Int J Clin Pharmacol Ther Toxicol; 1993 Sep; 31(9):461-6. PubMed ID: 8225696
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic effects of furosemide in patients with impaired renal function.
Traeger A; Stein G; Sperschneider H; Keil E
Int J Clin Pharmacol Ther Toxicol; 1984 Sep; 22(9):481-6. PubMed ID: 6500766
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacokinetics and pharmacodynamics of furosemide in liver cirrhosis].
Tesar V; Kotal P; Petrtýl J; Bukovská J; Kozáková M; Brodanová M; Horký K; Kordac V
Cas Lek Cesk; 1990 May; 129(21):657-64. PubMed ID: 2369756
[TBL] [Abstract][Full Text] [Related]
16. Urinary prostaglandin E2 excretion, sodium retention, and diuretic responsiveness in patients with chronic liver disease.
Rector WG
Am J Gastroenterol; 1987 Apr; 82(4):347-51. PubMed ID: 3471082
[TBL] [Abstract][Full Text] [Related]
17. Clinical consequences of the biphasic elimination kinetics for the diuretic effect of furosemide and its acyl glucuronide in humans.
Vree TB; van der Ven AJ
J Pharm Pharmacol; 1999 Mar; 51(3):239-48. PubMed ID: 10344623
[TBL] [Abstract][Full Text] [Related]
18. Comparison of diuretic effects and pharmacokinetics of torasemide and furosemide after a single oral dose in patients with hydropically decompensated cirrhosis of the liver.
Brunner G; von Bergmann K; Häcker W; von Möllendorff E
Arzneimittelforschung; 1988 Jan; 38(1A):176-9. PubMed ID: 3285830
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of furosemide in advanced renal failure.
Huang CM; Atkinson AJ; Levin M; Levin NW; Quintanilla A
Clin Pharmacol Ther; 1974 Oct; 16(4):659-66. PubMed ID: 4422027
[No Abstract] [Full Text] [Related]
20. Influence of hepatic insufficiency in pharmacokinetics of drugs: example for an anthranilic diuretic.
Dreux C; Passa P; Halter D
Methods Find Exp Clin Pharmacol; 1979 Dec; 1(5):289-96. PubMed ID: 552592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
